ID   SNU-668
AC   CVCL_5081
SY   SNU668; NCI-SNU-668
DR   EFO; EFO_0006759
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473141
DR   BioSample; SAMN10988049
DR   cancercelllines; CVCL_5081
DR   Cell_Model_Passport; SIDM01443
DR   CGH-DB; 128-1
DR   CGH-DB; 9016-4
DR   Cosmic; 685593
DR   Cosmic; 921602
DR   Cosmic; 1066232
DR   Cosmic; 1294956
DR   Cosmic; 1528879
DR   Cosmic; 2373754
DR   Cosmic; 2484962
DR   Cosmic; 2646593
DR   Cosmic; 2807651
DR   DepMap; ACH-000344
DR   EGA; EGAS00001000610
DR   GEO; GSM888725
DR   GEO; GSM1374897
DR   IARC_TP53; 7422
DR   KCLB; 00668
DR   LiGeA; CCLE_350
DR   PharmacoDB; SNU668_1477_2019
DR   Progenetix; CVCL_5081
DR   Wikidata; Q54955241
RX   PubMed=9033653;
RX   PubMed=10812166;
RX   PubMed=15723654;
RX   PubMed=19956504;
RX   PubMed=22460905;
RX   PubMed=24807215;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=29435981;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=32028591;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Population: Korean.
CC   Doubling time: 26 hours (PubMed=29435981).
CC   HLA typing: A*33:03,33:03; B*44:03,44:03; C*14:03,14:03 (PubMed=25960936).
CC   HLA typing: A*33:03,33:03; B*44:03,44:03; C*14:03,14:03; DQA1*05:02,05:02; DQB1*06:01,06:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000177777; Zygosity=Homozygous (PubMed=9033653; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Asn (c.644G>A); ClinVar=VCV000376662; Zygosity=Homozygous (PubMed=9033653; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.18%; Native American=0%; East Asian, North=71.14%; East Asian, South=25.86%; South Asian=0%; European, North=0%; European, South=1.82% (PubMed=30894373).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): KCLB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 11,12
ST   D18S51: 13
ST   D21S11: 30
ST   D3S1358: 16
ST   D5S818: 13
ST   D7S820: 9,11
ST   D8S1179: 14,15
ST   FGA: 23
ST   Penta D: 9
ST   Penta E: 16,19
ST   TH01: 8
ST   TPOX: 9
ST   vWA: 17
DI   NCIt; C5250; Gastric signet ring cell adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 34
//
RX   PubMed=9033653; DOI=10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G;
RA   Park J.-G., Yang H.-K., Kim W.-H., Chung J.-K., Kang M.-S., Lee J.-H.,
RA   Oh J.H., Park H.-S., Yeo K.-S., Kang S.H., Song S.-Y., Kang Y.K.,
RA   Bang Y.-J., Kim Y.I., Kim J.-P.;
RT   "Establishment and characterization of human gastric carcinoma cell
RT   lines.";
RL   Int. J. Cancer 70:443-449(1997).
//
RX   PubMed=10812166; DOI=10.1016/S0165-4608(99)00217-4;
RA   Chun Y.-H., Kil J.-I., Suh Y.-S., Kim S.-H., Kim H., Park S.-H.;
RT   "Characterization of chromosomal aberrations in human gastric
RT   carcinoma cell lines using chromosome painting.";
RL   Cancer Genet. Cytogenet. 119:18-25(2000).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=19956504; DOI=10.4143/crt.2005.37.1.1;
RA   Ku J.-L., Park J.-G.;
RT   "Biology of SNU cell lines.";
RL   Cancer Res. Treat. 37:1-19(2005).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=32028591; DOI=10.3390/cancers12020334;
RA   Kim J.W., Min A., Im S.-A., Jang H., Kim Y.J., Kim H.-J., Lee K.-H.,
RA   Kim T.-Y., Lee K.W., Oh D.-Y., Kim J.-H., Bang Y.-J.;
RT   "TDP1 and TOP1 modulation in olaparib-resistant cancer determines the
RT   efficacy of subsequent chemotherapy.";
RL   Cancers (Basel) 12:334.1-334.17(2020).
//